Field & Main Bank Raises Stock Holdings in Bristol Myers Squibb Company (NYSE:BMY)

Field & Main Bank raised its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 63.3% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 20,591 shares of the biopharmaceutical company's stock after acquiring an additional 7,985 shares during the quarter. Field & Main Bank's holdings in Bristol Myers Squibb were worth $1,256,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Silver Lake Advisory LLC increased its holdings in shares of Bristol Myers Squibb by 0.9% in the first quarter. Silver Lake Advisory LLC now owns 30,225 shares of the biopharmaceutical company's stock worth $1,843,000 after purchasing an additional 272 shares during the last quarter. Archford Capital Strategies LLC increased its holdings in shares of Bristol Myers Squibb by 56.4% in the first quarter. Archford Capital Strategies LLC now owns 18,472 shares of the biopharmaceutical company's stock worth $1,127,000 after purchasing an additional 6,664 shares during the last quarter. International Assets Investment Management LLC increased its holdings in shares of Bristol Myers Squibb by 16.2% in the first quarter. International Assets Investment Management LLC now owns 43,414 shares of the biopharmaceutical company's stock worth $2,648,000 after purchasing an additional 6,041 shares during the last quarter. Pacific Sage Partners LLC bought a new stake in shares of Bristol Myers Squibb in the first quarter worth about $212,000. Finally, PBMares Wealth Management LLC bought a new stake in Bristol Myers Squibb during the first quarter worth approximately $244,000. 76.41% of the stock is owned by institutional investors.

Insider Buying and Selling at Bristol Myers Squibb

In other Bristol Myers Squibb news, EVP Samit Hirawat acquired 4,250 shares of the firm's stock in a transaction dated Friday, April 25th. The stock was purchased at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the acquisition, the executive vice president now owns 83,513 shares in the company, valued at approximately $3,973,548.54. This trade represents a 5.36% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.09% of the company's stock.

Bristol Myers Squibb Stock Down 0.7%

NYSE BMY traded down $0.31 during midday trading on Friday, hitting $46.34. 21,851,928 shares of the company traded hands, compared to its average volume of 12,915,666. The company has a debt-to-equity ratio of 2.65, a current ratio of 1.28 and a quick ratio of 1.17. The company has a market cap of $94.31 billion, a PE ratio of 17.36, a price-to-earnings-growth ratio of 1.38 and a beta of 0.38. The company's 50-day simple moving average is $47.90 and its 200-day simple moving average is $53.94. Bristol Myers Squibb Company has a 52 week low of $39.35 and a 52 week high of $63.33.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.50 by $0.30. The business had revenue of $11.20 billion for the quarter, compared to analysts' expectations of $10.77 billion. Bristol Myers Squibb had a return on equity of 87.62% and a net margin of 11.38%. The business's revenue for the quarter was down 5.6% on a year-over-year basis. During the same quarter last year, the firm earned ($4.40) EPS. As a group, equities research analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, August 1st. Shareholders of record on Thursday, July 3rd will be given a dividend of $0.62 per share. The ex-dividend date of this dividend is Thursday, July 3rd. This represents a $2.48 annualized dividend and a yield of 5.35%. Bristol Myers Squibb's dividend payout ratio (DPR) is presently 92.88%.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Piper Sandler assumed coverage on Bristol Myers Squibb in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $65.00 price objective on the stock. William Blair reissued a "market perform" rating on shares of Bristol Myers Squibb in a research note on Friday, April 25th. Cantor Fitzgerald reissued a "neutral" rating and set a $55.00 price objective on shares of Bristol Myers Squibb in a research note on Tuesday, April 22nd. Wall Street Zen cut Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a research note on Friday, June 6th. Finally, Argus raised Bristol Myers Squibb to a "hold" rating in a research note on Friday, April 25th. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $58.00.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.